Lianxing Liu1, Yanling Hao, Zhenwu Luo, Yang Huang, Xintao Hu, Ying Liu, Yiming Shao. 1. State Key Laboratory for Infectious Diseases Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, 155 Changbai Road, Changping District, Beijing 102206, China.
Abstract
OBJECTIVE: To develop an effective HIV vaccine strategy that can induce cross-reactive neutralizing antibody. METHODS: Codon-optimized gp140 and gp145 env genes derived from HIV-1(cn54), a CRF07 B'/C recombinant strain, were constructed as DNA and recombinant Tiantan vaccinia (rTV) vaccines. The effect of heterologous immunization with gp140 and gp145 was tested in mice and guinea pigs. T cell responses were detected using the IFN-γ ELISPOT assay. A panel of primary isolates of clade B' and B'/C HIV-1 and TZM-bl cells was used to determine the neutralizing activity of immunized sera. RESULTS: The neutralizing antibodies (NAbs) induced by the heterologous immunogen immunization neutralized all HIV-1 B' and B'/C primary isolates in the guinea pig model. Gp145 and gp140 heterologous prime-boost induced the best neutralizing antibody response with a broad neutralizing spectrum and the highest titer of 1:270 at 6 weeks after the last inoculation. However, the T cell response to HIV-1 peptides was significantly weaker than the gp145+gp145 homologous prime-boost. CONCLUSIONS: This heterologous prime-boost immunization strategy could be used to design immunogen-generating broad neutralizing antibodies against genetic variance pathogens.
OBJECTIVE: To develop an effective HIV vaccine strategy that can induce cross-reactive neutralizing antibody. METHODS: Codon-optimized gp140 and gp145env genes derived from HIV-1(cn54), a CRF07 B'/C recombinant strain, were constructed as DNA and recombinant Tiantan vaccinia (rTV) vaccines. The effect of heterologous immunization with gp140 and gp145 was tested in mice and guinea pigs. T cell responses were detected using the IFN-γ ELISPOT assay. A panel of primary isolates of clade B' and B'/C HIV-1 and TZM-bl cells was used to determine the neutralizing activity of immunized sera. RESULTS: The neutralizing antibodies (NAbs) induced by the heterologous immunogen immunization neutralized all HIV-1 B' and B'/C primary isolates in the guinea pig model. Gp145 and gp140 heterologous prime-boost induced the best neutralizing antibody response with a broad neutralizing spectrum and the highest titer of 1:270 at 6 weeks after the last inoculation. However, the T cell response to HIV-1peptides was significantly weaker than the gp145+gp145 homologous prime-boost. CONCLUSIONS: This heterologous prime-boost immunization strategy could be used to design immunogen-generating broad neutralizing antibodies against genetic variance pathogens.
Authors: Bimal K Chakrabarti; Wing-pui Kong; Bei-yue Wu; Zhi-Yong Yang; Jacques Friborg; Xu Ling; Steven R King; David C Montefiori; Gary J Nabel Journal: J Virol Date: 2002-06 Impact factor: 5.103
Authors: Timothy Fouts; Karla Godfrey; Kathryn Bobb; David Montefiori; Carl V Hanson; V S Kalyanaraman; Anthony DeVico; Ranajit Pal Journal: Proc Natl Acad Sci U S A Date: 2002-08-21 Impact factor: 11.205
Authors: Z Hel; W P Tsai; A Thornton; J Nacsa; L Giuliani; E Tryniszewska; M Poudyal; D Venzon; X Wang; J Altman; D I Watkins; W Lu; A von Gegerfelt; B K Felber; J Tartaglia; G N Pavlakis; G Franchini Journal: J Immunol Date: 2001-12-15 Impact factor: 5.422
Authors: Markus Koch; Marie Pancera; Peter D Kwong; Peter Kolchinsky; Christoph Grundner; Liping Wang; Wayne A Hendrickson; Joseph Sodroski; Richard Wyatt Journal: Virology Date: 2003-09-01 Impact factor: 3.616
Authors: Veena Menon; Victor I Ayala; Sneha P Rangaswamy; Irene Kalisz; Stephen Whitney; Lindsey Galmin; Asma Ashraf; Celia LaBranche; David Montefiori; Nikolai Petrovsky; Vaniambadi S Kalyanaraman; Ranajit Pal Journal: J Gen Virol Date: 2017-07-31 Impact factor: 3.891
Authors: J Hinkula; S Petkov; K Ljungberg; D Hallengärd; A Bråve; M Isaguliants; T Falkeborn; S Sharma; V Liakina; M Robb; M Eller; B Moss; G Biberfeld; E Sandström; C Nilsson; K Markland; P Blomberg; B Wahren Journal: Heliyon Date: 2017-06-29